RISK-BENEFIT ANALYSIS AND RISK MINIMIZATION OF QUINAPRIL: A REVIEW
Anjo Sunny, M. Arif Khan, Darpelly Mahesh, Nikhil Singh Chauhan, Ritu Mishra, Namindla Presila and Asa Samuel
DOI : 10.3844/ajptsp.2014.68.74
American Journal of Pharmacology and Toxicology
Volume 9, Issue 1
The purpose of this review is to give the readers an insight about the risks and benefits of ’quinapril’, a potent Angiotensin Converting Enzyme Inhibitor (ACEI). Quinapril is a highly effective novel drug indicated for treatment of congestive heart failure and hypertension. Despite of the fact that safety profile is quite well with low incidence of adverse effects, an attempt has been made to minimize the risks and subsequently minimizing the adverse consequences of this competitive inhibitor, thereby increasing the benefits of this enzyme inhibitor in day to day clinical practice.
© 2014 Anjo Sunny, M. Arif Khan, Darpelly Mahesh, Nikhil Singh Chauhan, Ritu Mishra, Namindla Presila and Asa Samuel. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.